Clearbridge Small Cap Growth Strategy Adds Dyne Therapeutics to Portfolio in Q4

ClearBridge Small Cap Growth Strategy added Dyne Therapeutics (DYN) in Q4 2025, citing its potential for value creation due to limited existing treatment options and encouraging early data. The Strategy underperformed the Russell 2000 Growth Index in Q4, driven by market reactions to earnings disappointments in the technology sector and a biotech rally. Despite this, the Strategy remains optimistic about the favorable backdrop for small-cap growth stocks in 2026.